IP Commercializer PureTech's CEO Outlines 2018 Roadmap After Financing

Daphne Zohar tells Scrip PureTech will use $100m placing to develop Boston-based group's growth-stage affiliates and advance its "BIG" proprietary pipeline of brain-immune-gut assets.

Pipeline
PureTech Motoring "Full Speed Ahead" On Pipeline • Source: Shutterstock

In its latest corporate financing, UK-quoted IP commercializer PureTech Health PLC has raised $100m for use advancing therapies within its stable of incubated affiliates and its own growing pipeline of proprietary assets, which CEO Daphne Zohar says "focus on cross-talk and biological processes associated with the brain-immune-gut interface."

In an interview with Scrip, Zohar said PureTech would use the placing to support its more advanced affiliates, such as...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.